– UK, Guildford – ANGLE plc (LON: AGL | OTC: ANPCY), a world-leading liquid biopsy company announced the appointment of current independent Non-executive Director Dr. Jan Groen as Chair of its Board of Directors with immediate effect, succeeding Garth Selvey who will retire in September.
About Dr. Jan Groen
Dr. Jan Groen has over twenty years of experience in medical diagnostics covering both pharma and clinical sales, which provides critical market insight as ANGLE drives forward its commercial product roll-out and the expansion of its clinical laboratories and CTC services. Jan joined the ANGLE Board as a Non-executive Director in November 2018. Jan is currently the CEO and Chairman at Intravacc B.V. and was previously the CEO of MDxHealth, a Euronext-listed genomic diagnostics company specializing in prostate cancer, and President and COO of Agendia, a company specializing in breast cancer.
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with sample-to-answer solutions. ANGLE’s proven patent-protected circulating tumor cell harvesting technology is known as the Parsortix system.
ANGLE’s Parsortix system is FDA-cleared for its intended use in metastatic breast cancer and is currently the first and only FDA-cleared medical device to harvest intact circulating cancer cells from the blood.
For more information: https://www.angleplc.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
